Guidelines for depot antipsychotic treatment in schizophrenia

European Neuropsychopharmacology

Volumn 8, Issue 1, 1998, Pages 55-66

  Kane, John M ^a   Aguglia, Eugenio ^b   Altamura, A Carlo ^c   Gutierrez, José Luis Ayuso ^d   Brunello, Nicoletta ^e,n   Fleischhacker, W Wolfgang ^f   Gaebel, Wolfang ^g   Gerlach, Jes ^h   Guelfi, Julien D ⁱ   Kissling, Werner ^j   Lapierre, Yvon D ^k   Lindström, Eva ^l   Mendlewicz, Julien ^m   Racagni, Giorgio ⁿ   Carulla, Luis Salvador ^o   Schooler, Nina R ^p  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Institute of Psychiatric Clinic   (Italy)

^d Psiquiatria   (Spain)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^g Rheinische Landesklinik   (Germany)

^h Sct Hans Hospital   (Denmark)

ⁱ HÔPITAL PAUL BROUSSE   (France)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY OF OTTAWA   (Canada)

^l UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^m ERASME HOSPITAL   (Belgium)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o 11405 Jerez de la Frontera ^*  (Spain)

^p UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

Depot antipsychotics; Relapse; Schizophrenia; Treatment

Indexed keywords

FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; FLUSPIRILENE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; PIPOTIAZINE PALMITATE;

HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0031983904     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00045-X     Document Type: Article

References (79)

1. Adamson L., Curry S.H., Bridges P.K., Firestone A.F., Lavin N.I., Lewis D.M., Watson R.D., Xavier C.M., Anderson J.A. Fluphenazine decanoate trial in chronic inpatient schizophrenics failing to absorb oral chlorpromazine. Dis. Nerv. System. 33:1973;181-191.
2. Altamura, A.C., Colacurcio, F., Mauri, M.C. et al., 1990a. Haloperidol decanoate in chronic schizophrenia: a follow up study of 12 months with plasma levels. Prog. Neuropsychopharmacol. Biol. Psychiatry 14, 25-35.
3. Altamura, A.C., Mauri, M.C., Girardi, T., Panetta, B., 1990b. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. Int. J. Clin. Pharmacol. Res. 10 (4), 223-228.
4. Angst J., Bech P., Bruinvels J., Engel R.R., Ferner U., Guelfi J.D., Lingjaerde O., Muller-Oerlinghausen B., Paes de-Sousa M., Paykel E.et al. Report on the fifth consensus conference: methodology of long-term clinical trials in psychiatry. Pharmacopsychiatry. 27(3):1994;101-107.
5. Awad A.G. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp. Commun. Psychiatry. 43(3):1992;262-265.
6. Awad A.G., Hogan T. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr. Scand. 380(suppl):1994;27-32.
7. Barnes T.R.E., Curson D.A. Long-term depot antipsychotics: A risk-benefit assessment. Drug Safety. 10:1994;464-479.
8. Belanger M.C., Chouinard G. Technique for injecting long-acting neuroleptics. Br. J. Psychiatry. 141:1982;316.
9. Bland R.C., Parker J.H., Orn H. Prognosis in schizophrenia: A ten year follow-up of first admissions. Arch. Gen. Psychiatry. 33:1976;949-954.
10. Brown G.W., Birley J.L.T., Wing J.K. Influence of family life on the course of schizophrenic disorders: A replication. Br. J. Psychol. 121:1972;241-248.
11. Carpenter W.T., Stephen J.C., Rey A.C., Hanlon T.E., Heinrichs D.W. Psychopharmacol. Bull. 18:1982;21-23.
12. Carpenter W.T., Heinrichs D.W. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophrenia Bull. 9:1983;533-542.
13. Carpenter W.T., Heinrichs D.W., Hanlon T.E. A comparative trial of pharmacologic strategies in schizophrenia. Am. J. Psychiatry. 144:1987;1466-1470.
14. Carpenter W.T., Hanlon T.E., Heinrichs D.W., Summerfelt A.T., Kirkpatrick B., Levine J., Buchanan R.W. Continuous versus targeted medication in schizophrenic out-patients: outcome results. Am. J. Psychiatry. 147:1990;1138-1148.
15. Collins E.J., Hogan T.P., Deasi H. Measurement of therapeutic response in schizophrenia: A critical survey. Schizophr. Res. 5(3):1991;249-253.
16. Davies L.M., Drummond M.F. Economics and schizophrenia. Br. J. Psychiatry. 165(suppl. 25):1994;18-21.
17. Davis, J.M., Barter, J.T., Kane, J.M., 1989. Antipsychotic drugs. In: Kaplan, H.I., Sadock, B.J. (Eds.), Comprehensive Textbook of Psychiatry. Williams and Wilkins, Baltimore, pp. 1591-1626.
18. Davis J.M., Matalon L., Watanabe M.D., Blake L. Depot antipsychotic drugs. Place in therapy. Drugs. 47(5):1994;741-773.
19. Drake R., Gates C., Cotton P.C., Whitaker A. Suicide among schizophrenics: Who is at risk? J. Nerv. Ment. Dis. 172:1984;613-617.
20. Ereshefsky L., Jann M.W., Saklad S.R.et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol. Psychiatry. 40:1985;329-332.
21. Ereshefsky L., Saklad S.R., Jann M.W., Davis C.M., Richards A. Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. J. Clin. Psychiatry. 45(suppl):1984;50-59.
22. Ereshefsky L., Saklad S.R., Tran-Johnson T., Toney G., Lyman R.C. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacol. Bull. 26:1990;108-114.
23. Forrest F.M., Forrest I.S., Mason A.S. Review of rapid urine tests for phenothiazine and related drugs. Am. J. Psychiatry. 118:1961;300-307.
24. Forsman A., Ohman R. Applied pharmacokinetics of haloperidol in man. Curr. Ther. Res. 21:1977;245-255.
25. Frankenburg F.R., Hegarty J.D. Cost considerations in the treatment of schizophrenia. CNS Drugs. 5:1996;75-82.
26. Gaebel W., Frick U., Kopcke W., Linden M., Müller P., Müller-Spahn F., Pietzcker A., Tegeler J. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br. J. Psychiatry. 163(suppl. 21):1993;8-12.
27. Gaebel, W., Awad, G., 1994. Prediction of Neuroleptic Treatment Outcome in Schizophrenia-Concepts and Methods, Springer, Vienna.
28. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch. Gen. Psychiatry. 52:1995;173-188.
29. Glazer W.M., Kane J.M. Depot neuroleptic therapy: An underutilized treatment option. J. Clin. Psychiatry. 53:1992;426-433.
30. Haman G.L., Egan T.M., Wells B.G.et al. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/ml J. Clin. Psychiatry. 51:1990;502-504.
31. Hale A.S., Wood C. Comparison of direct treatment costs for schizophrenia using oral and depot neuroleptics: a pharmacoeconomic analys. Br. J. Med. Econ. 10:1996;37-45.
32. Herz M.I., Melville C.H. Relapse in schizophrenia. Am. J. Psychiatry. 137:1980;801-805.
33. Herz M.I., Szyinanski H.V., Simon J.C. Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am. J. Psychiatry. 139:1982;918-922.
34. Herz M.I., Glazer W.M., Moster M.A., Sheard M.A., Szymanski H.V., Hafez H., Mirza M., Vana J. Intermittent vs maintenance medication in schizophrenia: Two-year results. Arch. Gen. Psychiatry. 48:1991;333-339.
35. Hogan T.D., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenia: Reliability and discriminative validity. Psychol. Med. 13:1983;177-183.
36. Hogarty G.E., Goldberg S.G., Schooler N.R. Drug and sociotherapy in the aftercare of schizophrenic patients: Ill Adjustments of nonrelapsed patients. Arch. Gen. Psychiatry. 31:1974;609-618.
37. Hogarty G.E., McEvoy P., Munetz M., DiBarry A.L., Bartone P., Cather R., Cooley S.J., Uirich R.F., Carter M., Madonia M.J. Dose of fluphenazine, familial expressed emotions, and outcome in schizophrenia: results of a two-year controlled study. Arch. Gen. Psychiatry. 45:1988;797-805.
38. Jeste D.V., Caligiuri M.P. Tardive dyskinesia. Schizophr. Bull. 19:1993;303-315.
39. Johnson D.A., Ludlow J.M., Street K., Taylor R.D. Double blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br. J. Psychiatry. 151:1987;634-638.
40. Jolley A.G., Hirsch S.R., McRink A., Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. Br. Med. J 298:1989;985-990.
41. Jolley A.G., Hirsch S.R., Morrison E., McRink A., Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at two years. Br. Med. J 301:1990;837-842.
42. Kane J.M., Rifkin A., Woemer M.G., Reardon G., Sarantak S., Schiebel D., Ramosior J. Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch. Gen. Psychiatry. 40:1983;893-896.
43. Kane J.M., Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol. Bull. 21:1985;23-27.
44. Kane J.M. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. J. Clin. Psychopharmacol. 6:1986;205-235.
45. Kane, J.M., Jeste, D.V., Bames, T.R.E., et al., 1992. American Psychiatric Association Task Force Report on Tardive, Dyskinesia, American Psychiatric Press, Washington, DC.
46. Kane, J.M., 1995. Tardive dyskinesia. Paper presented at International Congress on Schizophrenia Research, April 10-13, Warm Springs, Virginia.
47. Kane J.M. Schizophrenia. N. Engl. J. Med. 334(1):1996;34-41.
48. Kinon B.J., Kane J.M., Chakos M., Munne R. Possible predictors of neuroleptic-resistant schizophrenic relapse: Influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol. Bull. 29(3):1993;365-369.
49. Kreisman D., Blumenthal R., Borenstein M., Woerner M., Kane J.M., Rifkin A., Reardon G. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: The family's view. Psychiatry. 51:1988;3-13.
50. Lauer G., Stegmuller-Koenemund U. Domain-specific subjective quality of life and illness-related limitations of schizophrenic patients. Psychiatr. Pract. 21(2):1994;70-73.
51. Levine J., Schooler N.R., Severs J.et al. Discontinuation of oral and depot fluphenasine in schizophrenic patients after one year of continuous medication: a controlled study. Adv. Bioch. Psychopharmacol. 24:1980;483-493.
52. Lieberman J.A., Saltz B.L., Johns C.A., Pollack S., Borenstein M., Kane J.M. The effects of clozapine on tardive dyskinesia. Br. J. Psychiatry. 158:1991;503-510.
53. Mann J.J. How medication compliance affects outcome. Psychiatr. Ann. 16:1986;567-570.
54. Marder S.R., vanPutten T., Mintz J., Mckenzie J., Lebell M., May P.R.A. Costs and benefits of two doses of fluphenazine. Arch. Gen. Psychiatry. 41:1984;1025-1029.
55. Marder S.R., vanPutten T., Mintz J., Lebell M., May P.R.A. Low and conventional dose maintenance therapy with fluphenazine decanoate: Two year outcome. Arch. Gen. Psychiatry. 44:1987;518-521.
56. Marder S.R. The role of dosage and plasma levels in neuroleptic relapse prevention. Acta Psych. Scandinav. 382:1994;25-27.
57. May P.R.A., Tuma A.H., Dixon W.J. Schizophrenia: A follow-up study of five forms of treatment. Arch. Gen. Psychiatry. 38:1981;776-784.
58. McEvoy J.P., Howe A.C., Hogarty G.E. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and non-compliant schizophrenic patients. J. Nerv. Ment. Dis. 172(7):1984;412-416.
59. Meise U., Rössler W., Fleischhacker W.W. Outpatient care in schizophrenia: treatment considerations. CNS Drugs. 1(4):1994;254-262.
60. Miles P. Conditions predisposing to suicide: A review. J. Nerv. Ment. Dis. 164:1977;231-246.
61. Perel J.M. Compliance and optimal dosage during maintenance therapy: Pharmacokinctic and analytic issues. J. Clin. Chem. 34:1988;881-887.
62. Pietzcker A., Gaebel W., Köpcke W., Linden M., Müller P., Müller-Spahn F., Schussler G., Tegeler J. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients: Preliminary report. Pharmacopsychiatry. 19:1986;161-166.
63. Pietzcker A., Gaebel W., Köpcke W., Linden M., Müller P., Müller-Spahn F., Tegeler J. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia-Two year results of a German multicenter study. J. Psychiatr. Res. 27:1993;321-339.
64. Pikney A.A., Gerber G.J., Lafave H.G. Quality of life after psychiatric rehabilitation: the clients' perspective. Acta. Psychiatr. Scand. 83(2):1991;86-91.
65. Radomsky, E.D., 1995. Measurement and assessment of compliance with an oral haloperidol regimen. Doctoral Dissertation, Department of Psychology, University of South Carolina.
66. Rice, P., Miller, L.S., 1996. The economic burden of schizophrenia; conceptual and methodological issues, and costs estimates. In: Moscarelli, M., Rupp, A., Sartorius, N., (Eds.), Handbook of Mental Health Economics and Healthy Policy. vol. 1, Schizophrenia, Wiley and Sons, Chichester, pp. 321-334.
67. Saltz B.L., Woemer M.G., Kane J.M., Lieberman J.A., Alvir J.M., Bergmann K.J., Blank K., Koblenzer J., Kahaner K. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 266:1991;2402-2406.
68. Schooler, N.R., 1985. Treatment of schizophrenia: Maintenance strategies and pharmacologic tactics. In: Alpert M., (Ed.), Controversies in Schizophrenia, Guilford Press, New York, pp. 366-380.
69. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M. Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome. Schizophr. Res. 9:1993;260.
70. Schooler N.R., Keith S.J., Severe J.B.et al. Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Psychiatric Quart. 66:1995;279-292.
71. Schulz P., Rey M.J., Dick P., Tissot R. Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long acting injectable neuroleptics. Intl. Clin. Psychopharmacol. 4:1989;105-114.
72. Schulze-Monking H., Buchkremer G. Emotional family atmosphere and relapse: investigations on the role of relapse. definition, duration of illness and resignation of relatives. Eur. Psychiatry. 10:1995;85-91.
73. Shalev A., Hermesh H., Rothberg J., Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr. Scand. 87:1993;86-91.
74. Sleator E.K. Measurement of compliance. Psychopharmacol. Bull. 21(3):1985;1089-1093.
75. Smith K., Shah A., Wright K., Lewis G. The prevalence and costs of psychiatric disorders and learning disabilities. Br. J. Psychiatry. 166:1995;9-18.
76. Steingard S., Allen M., Schooler N.R. A study of the pharmacologic treatment of medication compliant schizophrenics who relapse. J. Clin. Psychiatry. 55:1994;470-472.
77. vanPutten T., May P.R.A. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Arch. Gen. Psychiatry. 35:1978;447-480.
78. Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz-Lennon M., Frances A. Rating of Medication Influences (ROMI) Scale in Schizophrenia. Schizophr. Bull. 20(2):1994;297-306.
79. Young J.L., Zonana H.V., Shepler L. Medication compliance in schizophrenia: Codification and update. Bull. Am. Acad. Psychiatry Law. 14(2):1986;105.